Loading viewer...
investor_presentation
Format: PDF investor_presentation
OPKO Health presents its diverse global portfolio strategy focused on growing its commercial HGH franchise and specialty testing segments. The company highlights NGENLA, a long-acting growth hormone therapy partnered with Pfizer in a $5.5B market, alongside next-generation multispecific antibody programs in immunology and infectious disease developed with BARDA, Merck, and NIH support.
investor_presentation
25 Pages
OPKO Health Investor Presentation — September 2017
investor_presentationinvestor_presentation
23 Pages
OPKO Health Investor Presentation — September 2017
investor_presentationinvestor_presentation
23 Pages
investor_presentation
6 Pages
BlackRock
Honeywell International Investor Presentation — May 2022
investor_presentationinvestor_presentation
8 Pages
Honeywell International Inc.
